Since 1986, we and others have detected high levels of the sialyl Lea antigen (NeuAca2-3 GalPl-3 [Fucal-41GlcNAcpl-. . .) in the sera of many CF patients (1) (2) (3) (4) . The antigen is present on mucins in the sera of patients with CF (5) and adults who have pancreatic or other gastrointestinal cancers. Sialyl Lea antigen may be used as a tumor marker (6) . Sialyl Lea antigen (or mucin) levels in serum are related to the age, clinical status, and pulmonary status of CF patients (7, 8) . The purpose of the present study was to compare serum antigen levels of healthy newborns or infants and young children who had lung diseases (e.g. asthma or bronchopulmonary dysplasia) with serum antigen levels of infants and young children who had CF.
MAb that specifically recognize this carbohydratc cpitope, including CA 19-9, have been used to quantify the antigen in patient sera (9) . The antigen was originally examined as a tumor marker (6) , but has limited utility for diagnostic pur-poses, because expression of the antigen depends on expression of several gene products (10) . Approximately 7% of the population lacks the Le gene, and the assay will be uninformative for these patients. Levels of antigen also vary due to competition by other glycosyltransferases for the precursor oligosaccharide Galpl-3GlcNAcpl-R during biosynthesis of sialyl Lea (10) (11) (12) . Thus, ~e\atients, expressing both the Le and Se genes, have lower levels of antigen than Lea patients expressing only the Le gene (10) (11) (12) . Therefore, absolute levels of antigen cannot be directly correlated with disease status in individual patients. By population studies and longitudinal studies of individual patients, however, antigen levels have been correlated with recurrence or progression of tumors in patients with mucin-secreting adenocarcinomas and with age, clinical status, and pulmonary status of patients with CF (7, 8) .
METHODS

Chemical/immunologic.
The Lewis blood group type of 11 1 healthy newborns was determined by a method similar to that of Karlsson and Larson (13) . Newborns' meconium in labeled disposable diapers was promptly placed on dry ice in a Styrofoam container, which was then transported daily to the laboratory for storage in a -70°C freezcr in individual plastic bags. After thawing, glycolipid was extracted from 1 g wet weight of meconium by two extractions of chloroform:methanol:water (5:10:3) and desalted on Sephadex G-25 columns eluted with ch1oroform:methanol:water (60:30:4.5). Glycolipids were detected by immunostaining after separation on Merck HPTLC plates (14) . Each sample was typed for its Lewis antigen using MAb to Lewis blood group antigens Led and L e t produced by hybridoma cell lines 151-6-A7-9 and 143-2-A6-11, respectively (American Typc Culture Collection HB8324 and HB8325, Rockville, MD). For each sample, 1-and 5-mg equivalcnts of tissue were applied. Internal standards were total lipid extract from colorectal carcinoma cell line SW1116 (American Type Culture Collection HB8059) and human Led and ~e " ceramide. Iz51-labeled protein A and goat anti-mouse IgM were used to detect Lea and ~e~ antibody binding, respectively. Plates were dried and exposed to Kodak XAR5 film.
Levels of sialyl Lea antigen in sera from umbilical cord blood of the newborns or from venous blood of babies or children were measured using CA 19-9 immunometric assay (kits were provided by Centocor, Malvern, PA). This method has been described by Del Villano and collcagues (9) .
Patients. Four groups were studied, and the demographics of each are provided in Table 1 . All but thrce of the CF patients were initially detected by the neonatal immunoreactive trypsin assay (15) . Thcir diagnoses were later confirmcd by quantitative pilocarpine iontophoresis (16) with sweat chloride conccntrations repeatedly greater than 60 mmol/L. The CF paticnts' blood samples were obtained by phlebotomy while they were outpatients at the University of Colorado Health Sciences Center in Denver. Table 2 provides the CF patients' clinical characteristics. Genotypes for 26 of 39 CF patients were determined by standard means (17) .
The 38 asthmatic patients' venous blood was samplcd while they were inpatients at the National Jewish Asthma Rescarch Center in Denver. The Asthma Research Ccnter inpatients usually have asthma that is severe and refractory to treatment.
The 17 bronchopulmonary dysplasia patients had all suffered stage IV lung disease (18) and some were oxygen-dependent at the timc their venous blood was sampled during clinic visits at the University of Colorado Health Sciences.
The 111 neonates were all term infants who generally had Apgar scores greater than 7 at 1 and 5 min after delivery. Two sick neonates were inadvertently included. One term neonate had Apgar scores of 4 at 1 min and 9 at 5 min and was later 
Statistical analyses.
A one-way analysis of variance (1 X 4) with groups as a between-subjects factor was conducted to determinc whether thc mean serum antigen lcvels of the four groups differed. Duncan's multiplc range test was used to cvaluate the differences among the group's mcan serum antigen levels. Pearson correlation coefficients wcre used to dctermine the rclation between serum antigen level and patients' age and gender. A t test for two groups of unequal size (two-tailed) was used to determine the significancc of differcnces betwecn mean serum antigen levels of Led or LC' neonates and mean serum antigen levels of CF patients with respiratory complaints compared with those CF paticnts with either no disease or who had gastrointestinal or nutritional manifestations of CF. Data are expresscd as mean units of antigen per mL of serum + SEM.
RESULTS
Our major finding was that the CF patients' mean scrum sialyl Led antigen level was significantly highcr than the mean serum antigen levels of the other three groups (Fig. 1 ). The one-way analysis of variance revealed a significant difference among mean serum antigen levels [F (3, 205) = 6.66, p < 0.011. Duncan's multiple range test revealed that the mean serum mucin level of the CF group was significantly different from the means of the other three groups (p < 0.05) but that the othcr three groups were not significantly different from one another. Furthermore, all three non-CF groups' mean serum antigen levels were well within the limits of more than 2000 normal adult blood donors' serum sialyl Led levels, 99% of whom had sialyl Lea antigen levels less than 37 U/mL (19) .
Of 11 1 neonates, therc were 97 who expressed Leb antigen, nine who expressed only Le", and five who were Led-"-. As expected, the nine normal neonates who expressed only the Lea blood group antigen in their meconium glycolipids had, on average, significantly higher serum antigen levels than their LC" counterparts [t (104) = 7.52, p < 0.0011. The range of individual serum antigen levels was great, being <8 U/mL serum to 56 U/mL for the Led neonates and <8 to 102 U/mL for ~e ' neonates. One of five ~e"-'-neonates had a barely detectable serum antigen level of 10 U/mL, but the other four -" -neonates' serum sialyl Led levels were all <8 U/mL, the lower threshold of dctection. There was no statistically significant correlation between serum antigen levels and age or gender, either within groups or among all patients together.
Twenty-six CF patients were genotyped. Fourteen patients were AF5081AF508, 9 were AF508/?, two were AF508/R553X, and one was AF508lG +A. Six CF patients initially had 72-h stool collections with <IS% fecal fat concentration, although only one patient maintained pancreatic sufficiency by 1 y of age. Of the six CF patients with initial pancreatic sufficiency, two had the AF508lAF508 genotype, one was AF508/?, and one was AF5081R553X; the remaining CF patient who did not have pancreatic insufficiency at 1 y of age was of unknown genotype.
CF patients with principally respiratory manifestations of that disease had a significantly elevated mean antigen level 0 Figure 2 .
DISCUSSION
The present data demonstrate a specific elevation of sialyl Lea antigen levels in infants and young children who have CF. We have reported previously that mucin levels are elevated in older CF patients and increase with age. Previous results suggest that the mucin antigen in serum is largely of pulmonary origin (5) . How mucin secreted in the lung enters the circulation, however, is unclear. Lack of correlation between mucin levels and colonization by Pseudomonas aeruginosa (7) and detection of elevated mucin levels in the present study in infants who are less likely to have chronic infections indicates that extensive tissue damage secondary to infection is not required for antigenemia. Correlation of antigen levels in individual patients with changes in clinical status, however, suggests that the inappropriate secretion of antigen in serum depends on specific clinical manifestations of the disease rather than being a constitutive effect of the CFTR defect.
The CFTR gene is selectively expressed in serous tubules and a subpopulation of epithelial cells in collecting ducts and ciliated ducts of submucosal glands of normal individuals (20) . Apical membrane expression of the CFTR protein at these sites is lost in CF patients. This loss may directly alter the composition or physical properties of mucins secreted by the affected cells or may indirectly alter the viscoelastic properties of the secreted mucin through changes in the ionic composition of the collecting ducts. Resulting obstruction of the ducts can be observed even in infants (21, 22) and may lead to release of the mucin into the blood.
Current information suggests a pulmonary origin of the elevated sialyl Lea antigen (mucin) levels detected in the sera of many CF patients. First, serum mucin from a single CF patient most resembled human lung mucin with respect to carbohydrate and amino acid composition (5). Second, serum sialyl Lea antigen levels correlated with measures of lung disease in two studies of groups of CF patients (7, 8) . Third, of 39 CF patients in the present study, 22 had some evidence of lung disease when their blood was drawn. The amount of mucins from CF patients' lungs leaked into the circulation is probably quite large. This is consistent with the finding that to overwhelm the hepatic clearance of serum mucins from human cancers implanted in nude mice, massive tumor loads were required, the equivalent of a 1200-g malignancy in a 65-kg human (23) .
Two alternative explanations for sialyl Lea elevations in CF patients' sera must be addressed. One is that there is a genetic linkage between the CF locus and the genes for transferases that synthesize the sialyl Lea antigen. However, no association between the Lewis blood group and CF has been observed (24) . The gene for the Lewis fucosyltransferase is located on chromosome 19 (25, 26) , whereas the CF gene is on chromo-some 7 (27) (28) (29) . A second explanation is that more Lea CF patients were tested than were patients with Lea blood types in the other three groups. Enzyme competition for the carbohydrate substrate Galpl-3GlcNAc. . . leading to the synthesis of the sialyl Lea antigen and the ~e " antigen probably means people who are Lea will express more sialyl Lea on their mucins than will people whose blood type is Leb (11) (12) (13) (14) . Unfortunately, the CF patients' Lewis blood group types are unknown, but there is no obvious selection bias favoring such patients. Moreover, our own previous studies have demonstrated large elevations of sialyl Lea antigen among adult CF patients whose blood type is Leb (7) .
Another issue is our comparison of serum mucin levels of asthma and bronchopulmonary dysplasia patients with those of CF patients. It may be argued that patients with asthma and bronchopulmonary dysplasia do not chronically produce purulent sputum as do many CF patients, and therefore their serum mucin levels cannot be compared with those of CF patients. We believe that this issue has been resolved by two studies. First, Robinson et al. (30) found the mean serum mucin level detected by their MAb 17B1 was significantly higher in a group of adult CF patients than in normal control adult patients or adult patients with chronic obstructive lung disease who produced a teaspoonful to a half cupful of sputa daily. Second, in our 1989 study, we found the mean serum mucin level as detected with the CA 19-9 MAb to be significantly higher in 8 1 CF patients (adults and children) with Pseudomonas in their sputa than in six bronchiectatic non-CF adults who had Pseudomonas in their sputa. With the exception of similar serum mucin elevations in both CF and non-CF lung transplant patients (30) , elevated serum mucin levels are associated with CF lung disease rather than with either purulent or dry non-CF lung diseases.
We note that in CF pancreatic sufficiency or insufficiency is importantly influenced by genotype (31) . We therefore attempted to examine the relationship of serum sialyl Lea antigen levels to pancreatic sufficiency and to genotype. However, there were only six of 39 CF ~atients with ~ancreatic sufficiency, and pancreatic sufficiency was transient in all but one patient, so that any attempt to examine a degree of association between fecal fat concentration and serum sialyl Lea antigen level or genotype would have been complicated by the extremely low power of any statistical test on a sample this small. We note that in the present study, although the mean antigen level of CF patients with lung disease is significantly higher than that of CF patients free of either lung or gastrointestinal and nutritiollal disease, it is not significantly different from the mean serum antigen level of CF patients with digestive disease (Fig. 2) , but again, small sample size may preclude further detection of intra-CF group differences. Furthermore, we found in our 1989 study that elevated serum mucin levels in CF patients were related to lung disease; in that study, four CF patients with elevated serum mucin levels had insulindependent diabetes, a condition that probably precludes having enough pancreatic epithelia to secrete mucin. Therefore, we think it unlikely that there is a relationship between the CF patients' elevated serum sialyl Lea levels and their pancreatic statuses, and suggest that, in CF, elevated serum sialyl Lea levels are related to lung disease (phenotype) rather than to genotype.
In a previous study of 89 CF patients (7) , serum mucin levels significantly increased with age and degree of sickness. No relationship between age and serum mucin levels was noted in neonates and young children. The reasons for this apparent lack of agreement may be that CF patients in the present study were relatively well and had a limited age range (1 mo to 3 y), and thus differences in serum mucin levels at this early stage in the evolution of cystic fibrosis were too small to detect. In the 1989 study (7), the age range was from a few months to more than 40 y. Finally, because the Lewis blood group types of the CF patients in the present study are not known, it is possible that there were more ~e~ phenotype patients in this study than in the previous one (7), which may lead to less sialyl Led antigen on mucins and therefore smaller in-group serum antigen differences for reasons explained earlier.
We previously found that sialyl Le" antigen is present on mucins in high levcls in the sera of many CF patients and that preliminary evidence suggested that those levels were correlated positively with pulmonary disease and increasing age. Other investigators have confirmed our findings (8) . The present study extends these observations by demonstrating that even very young CF patients have elevated sialyl Le" levcls compared with serum antigen levels of normal babies or infants and young children who have lung diseases.
